Analyst Price Target is $10.00
▲ +2,234.81% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Freeline Therapeutics in the last 3 months. The average price target is $10.00, with a high forecast of $15.00 and a low forecast of $5.00. The average price target represents a 2,234.81% upside from the last price of $0.43.
Current Consensus is
Buy
The current consensus among 2 investment analysts is to buy stock in Freeline Therapeutics. This Buy consensus rating has held steady for over two years.
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
Read More